GLP-1 questions emerge for 2025 [Yahoo! Finance Canada]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance Canada
The weight-loss market began feeling some growing pains as the year ended, creating more wariness for the upcoming year. For 2025, competition and supply constraints are areas to watch. Between Novo Nordisk's ( NVO ) slightly disappointing results for its latest GLP-1 candidate, CagriSema, and questions that remain about Amgen's ( AMGN ) highly anticipated once-monthly injectable, MariTide, some wonder if the weight-loss drug market has reached its peak. Mizuho healthcare expert Jared Holz wrote in a note that it's doubtful "patients are seeking to lose more weight than what drugs like Zepbound and Wegovy are providing." Zepbound, Eli Lilly's ( LLY ) weekly injectable weight-loss treatment, provides up to 24% weight loss, while Wegovy from Novo Nordisk provides up to 16%. Novo's most recent clinical trial data for CagriSema showed 23% weight loss — putting it just under Lilly's ceiling for Zepbound. The company had indicated it expected higher results, and the stock slid on n
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Lilly asks to join lawsuit over compounded versions of its weight-loss drugs [CNBC]CNBC
- Could Trump Make A Big Weight Loss Drug Deal? [Forbes]Forbes
- GLP-1 questions emerge for 2025 [Yahoo! Finance]Yahoo! Finance
- Why Novo Nordisk (NVO) Dipped More Than Broader Market Today [Yahoo! Finance]Yahoo! Finance
- 3 Stocks That Could Be Monster Winners in 2025 [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 11/7/24 - Beat
NVO
Sec Filings
- 12/20/24 - Form 6-K
- 12/20/24 - Form 6-K
- 12/18/24 - Form 6-K
- NVO's page on the SEC website